Dexamethasone Implant in Pseudophakic and Nonglaucomatous Subgroup of Diabetic Macular Edema Patients: A Real Life Experience

2015 ◽  
Vol 26 (4) ◽  
pp. 351-355 ◽  
Author(s):  
Abdullah Ozkaya ◽  
Cengiz Alagoz ◽  
Nese Alagoz ◽  
Hasan Gunes ◽  
Ihsan Yilmaz ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Life Experience ◽  
Real Life ◽  
Dexamethasone Implant

scholarly journals Dexamethasone implant in diabetic macular edema in real-life situations

Eye ◽  
2015 ◽  
Vol 30 (3) ◽  
pp. 426-430 ◽  
Author(s):  
J Chhablani ◽  
P Bansal ◽  
D Veritti ◽  
S Sambhana ◽  
V Sarao ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Dexamethasone Implant

REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT

Retina ◽  
2017 ◽  
Vol 37 (4) ◽  
pp. 753-760 ◽  
Author(s):  
Ariane Malclès ◽  
Corinne Dot ◽  
Nicolas Voirin ◽  
Émilie Agard ◽  
Anne-Laure Vié ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Dexamethasone Implant ◽  
Life Study ◽  
Real Life Study

Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study

2020 ◽  
Vol 57 (12) ◽  
pp. 1413-1421 ◽  
Author(s):  
Thibaud Mathis ◽  
Théo Lereuil ◽  
Amro Abukashabah ◽  
Nicolas Voirin ◽  
Aditya Sudhalkar ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Dexamethasone Implant ◽  
Life Study ◽  
Long Term Follow Up ◽  
Real Life Study

scholarly journals Visual Acuity Gain Profiles and Anatomical Prognosis Factors in Patients with Drug-Naive Diabetic Macular Edema Treated with Dexamethasone Implant: The NAVEDEX Study

Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 194
Author(s):  
Mauricio Pinto ◽  
Thibaud Mathis ◽  
Pascale Massin ◽  
Jad Akesbi ◽  
Théo Lereuil ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Dexamethasone Implant ◽  
Stage Disease ◽  
Significant Difference ◽  
Functional Factors ◽  
Drug Naïve ◽  
Group B

The purpose of this study is to evaluate the visual acuity (VA) gain profiles between patients with drug-naive diabetic macular edema (DME) treated by dexamethasone implant (DEX-implant) and assess the baseline anatomical and functional factors that could influence the response to the treatment in real-life conditions. A retrospective, multi-center observational study included 129 eyes with drug-naive DME treated by DEX-implant. The Median follow-up was 13 months. Two groups of VA gain trajectories were identified—Group A, with 71% (n = 96) of patients whose average VA gain was less than five letters and Group B, with 29% (n = 33) of patients with an average gain of 20 letters. The probability of belonging to Group B was significantly higher in patients with baseline VA < 37 letters (p = 0.001). Ellipsoid zone alterations (EZAs) or disorganization of retinal inner layers (DRILs) were associated with a lower final VA (53.0 letters versus 66.4, p = 0.002) but without a significant difference in VA gain (4.9 letters versus 6.8, p = 0.582). Despite a low baseline VA, this subgroup of patients tends to have greater visual gain, encouraging treatment with DEX-implant in such advanced-stage disease. However, some baseline anatomic parameters, such as the presence of EZAs or DRILs, negatively influenced final vision.

Real-life experience of ranibizumab for diabetic macular edema in Taiwan

2018 ◽  
Vol 39 (7) ◽  
pp. 1511-1522 ◽  
Author(s):  
Meng-Ju Tsai ◽  
Yi-Ting Hsieh ◽  
Yi-Jie Peng
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Life Experience ◽  
Real Life

Treatment of Diabetic Macular Edema with Multiple Dexamethasone Intravitreal Implants: Evidence from Real-Life Experience

2019 ◽  
Vol 243 (6) ◽  
pp. 413-419 ◽  
Author(s):  
Daniele De Geronimo ◽  
Paola Giorno ◽  
Fabio Scarinci ◽  
Antonluca Boninfante ◽  
Monica Varano ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Life Experience ◽  
Real Life ◽  
Vitreous Hemorrhage ◽  
Previous Treatment ◽  
Anti Vegf ◽  
Positive Balance

<b><i>Objective:</i></b> To gain information about multiple dexamethasone intravitreal implant (DEX-I) injections in diabetic macular edema (DME) eyes in real-life clinical settings. <b><i>Methods:</i></b> Patients with DME treated with multiple (≥5) DEX-I injections between January 1, 2014, and December 31, 2018, were retrospectively enrolled regardless of previous treatment with anti-VEGF agents. All patients were evaluated with best-corrected visual acuity (BCVA) in logMAR, ocular fundus, and spectral domain optical coherence tomography (SD-OCT) at baseline and at 3 months after the last DEX-I injection. Multiple DEX-I injections were administered when necessary in case of DME recurrence. Main efficacy measures were changes in BCVA and central retinal thickness (CRT) from baseline to 3 months after the last DEX-I injection; main secondary measures were an increase in intraocular pressure (IOP), the need for cataract surgery, endophthalmitis, and vitreous hemorrhage. <b><i>Results:</i></b> Seventeen patients (18 eyes) with DME and mean age (± SD) of 54.3 ± 8.16 years were treated with DEX-I injections between 2014 and 2018. The majority of eyes (77.8%) had been treated with a mean of 6.3 ± 3.2 anti-VEGF agents before switching to DEX-I. During a mean follow-up period of 37.6 months and after a mean number of 5.9 DEX-I injections, visual acuity improved or stabilized in 77.8% of all eyes, accompanied by a significant reduction in CRT. An increase in IOP was recorded in 38.8% of all patients, while a surgical procedure was needed for cataract in 73.3% of all phakic patients. <b><i>Conclusions:</i></b> In this real-life experience in Italy, multiple DEX-I treatments showed good efficacy with no new safety concerns. The follow-up duration of &#x3e;3 years and a greater number of DEX-I intravitreal injections compared to other observations confirm the positive balance between risks and benefits of DEX-I in the long term.

Sign in / Sign up

Export Citation Format

Share Document